Medtronic's Fair Value: DCF Analysis Suggests Undervaluation at Current Price

miércoles, 4 de febrero de 2026, 11:57 pm ET1 min de lectura
MDT--

Medtronic's recent share price gains of 1.0% over 7 days, 4.6% over 30 days, 6.0% year to date, 14.6% over 1 year, and 30.4% over 3 years have led to a valuation score of 4 out of 6, indicating the stock is undervalued on several metrics. A discounted cash flow analysis suggests Medtronic trades at a 3.8% discount to its intrinsic value of $105.86 per share, implying the stock is fairly valued.

Medtronic's Fair Value: DCF Analysis Suggests Undervaluation at Current Price

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios